Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
Sponsor: Anhui Provincial Hospital
Summary
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. The relatively low local control rate has been the bottleneck for further improvement of overall survival. Hypofraction radiotherapy has been validated to be able to increase the local control rate in two prospective trials. Therefore, this trial is designed to explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.
Official title: Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-small Cell Lung Cancer: A Phase II Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2022-03-01
Completion Date
2026-01-30
Last Updated
2026-09-25
Healthy Volunteers
Yes
Interventions
High-dose hypofractionated radiotherapy
Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f with one-year immunotherapy maintenance.
Low-dose hypofractionated radiotherapy
Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/12f with one-year immunotherapy maintenance.
Locations (1)
Anhui Provicial Hospital
Hefei, Anhui, China